[Postmenopausal osteoporosis. Bisphosphonates are not all equal].
D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D016568:Drugs, Generic / Q000008:administration & dosage / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005858:Germany; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010349:Patient Compliance; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D000068296:Risedronic Acid; D013997:Time Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D016568:Drugs, Generic; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate